Zak Mir takes a charting look at the latest requests, including Delta Gold Technologies plc (DGQ), Mkango Resources (MKA), Panther Metals PLC (PALM), Physiomics (PYC) and Upland Resources Ltd (UPL).
Zak Mir takes a charting look at the latest requests, including Delta Gold Technologies plc (DGQ), Mkango Resources (MKA), Panther Metals PLC (PALM), Physiomics (PYC) and Upland Resources Ltd (UPL).
Fulcrum Metals plc (AIM: FMET), a company pioneering the use of innovative cyanide-free technologies to recover precious and critical metals from mine waste and support site remediation, announces that it has
A bidding war between MGM and private equity players is said to be in the offing, according to M&A traders: the starting price is from north of 800p a share
Shuka Minerals Plc (AIM/AltX: SKA) has commenced Phase 1 drilling at the No.2 ore body within its Kabwe Zinc Mine project in Zambia, marking the start of a major exploration
Stocks in London are set to open lower on Friday, ahead of the latest UK house price data and following attacks that cast fresh doubt on the fragile ceasefire between
Norway has confirmed plans to revive three dormant North Sea gas fields, marking the first reopening of mothballed offshore fields in the region in nearly 30 years as Europe seeks
London stocks are set for a stronger open on Wednesday as easing geopolitical tensions and softer oil prices improve investor sentiment. Futures indicate the FTSE 100 will open around 106
North Yorkshire Council Planning Committee Decision regarding the Cloughton Well
Lloyds Bank Switching Offer Deadline Approaches for Account Holders Seeking Cashback Incentives
Asian equities pulled back from record levels as rising oil prices and renewed shipping disruptions in the Gulf weighed on sentiment.
London’s housing market faces a significant structural challenge as developers have shelved at least 42,000 new residential units, undermining the capital’s efforts to address an acute housing shortage. According to
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial